The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The disease-modifying potential of CALR-targeted therapies in MPNs
JAK inhibitors are a mainstay in the treatment of myeloproliferative neoplasms (MPNs), helping to reduce spleen volume and improve symptoms. However, these agents do not address the underlying cause of the disease. In this video, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, briefly comments on the disease-modifying potential of mutant calreticulin (CALR)-targeted therapies, which is a hot topic in the field of MPNs. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We have big expectations with these new strategies targeting the clone itself with specific drugs and not only JAK inhibition. That has very important issues that are mostly to address not only the mutant clones but also sometimes inflammation, for example for some of the JAK inhibitors and other targets. But here we are just targeting the malignant cell itself, the source of the cell and hopefully the leukemia-initiating cells...
We have big expectations with these new strategies targeting the clone itself with specific drugs and not only JAK inhibition. That has very important issues that are mostly to address not only the mutant clones but also sometimes inflammation, for example for some of the JAK inhibitors and other targets. But here we are just targeting the malignant cell itself, the source of the cell and hopefully the leukemia-initiating cells. So we hope that with this type of drugs we may eliminate the mutant clone, the malignant clone and hopefully maybe achieve a cure for some of these patients. That is not the case currently with JAK inhibitors.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
